Online citations, reference lists, and bibliographies.
← Back to Search

Acute And Longer-term Outcomes In Depressed Outpatients Requiring One Or Several Treatment Steps: A STAR*D Report.

A. Rush, M. Trivedi, S. Wisniewski, A. Nierenberg, J. Stewart, D. Warden, G. Niederehe, M. Thase, P. Lavori, B. Lebowitz, P. McGrath, J. Rosenbaum, H. Sackeim, D. Kupfer, J. Luther, M. Fava
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OBJECTIVE This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. METHOD A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of or=11 (HRSD(17)>or=14) defined relapse. RESULTS The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps. CONCLUSIONS When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.



This paper is referenced by
10.1097/JCP.0000000000001452
Combination of Tranylcypromine and Mirtazapine in Difficult-to-Treat Depression
E. Kavakbasi (2021)
10.3389/fpsyt.2021.617640
Factors Associated With Time to Achieve Employment Through Occupational Support Programs in Patients With Mood Disorders: 1 Year Naturalistic Study
T. Hayasaka (2021)
10.1093/ijnp/pyab013
Vasopressin V1B Receptor Antagonists as Potential Antidepressants
S. Chaki (2021)
10.1016/j.biopsych.2021.05.023
The Neurobiological Effects of Electroconvulsive Therapy Studied Through Magnetic Resonance: What Have We Learned, and Where Do We Go?
O. Ousdal (2021)
10.1038/s41386-020-00943-x
Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings
A. Athreya (2021)
10.1016/j.brs.2021.07.013
Day-to-day variability in motor threshold during rTMS treatment for depression: Clinical implications
G. Cotovio (2021)
10.1016/j.psychres.2020.113649
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression
A. Rothschild (2021)
10.1038/s41398-021-01560-y
Comparative efficacy and cognitive function of magnetic seizure therapy vs. electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis
Miao-Yi Chen (2021)
10.1145/3459930.3469528
Synthesized difference in differences
Eric V. Strobl (2021)
10.3390/ijms22147421
Molecular Basis of Late-Life Depression
C. Kuo (2021)
10.1097/JCP.0000000000001435
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials
Sigal Zilcha-Mano (2021)
10.1017/S2045796021000470
Exploring the cost-effectiveness of a Dutch collaborative stepped care intervention for the treatment of depression and/or anxiety when adapted to the Australian context: a model-based cost-utility analysis
Y. Y. Lee (2021)
10.1038/s41398-020-01156-y
Dentate gyrus activin signaling mediates the antidepressant response
Mark M. Gergues (2021)
10.12740/PP/ONLINEFIRST/132213
Analysis of efficacy and safety of electroconvulsive therapy in elderly patients: a retrospective study in the Polish population
A. Antosik-Wojcinska (2021)
10.1177/20451253211006508
Excess deaths in treatment-resistant depression
P. Brenner (2021)
10.14744/DAJPNS.2021.00115
Vortioxetine: a comprehensive update on a new-generation antidepressant
C. Evren (2021)
10.1007/s40263-021-00837-6
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study
Vera M. Ludwig (2021)
10.1177/11786469211039220
Neurotransmitter Precursor Amino Acid Ratios Show Differential, Inverse Correlations with Depression Severity in the Low and High Depression Score Range
K. Hüfner (2021)
10.3389/fpsyt.2021.631475
Association Between OLIG2 Gene SNP rs1059004 and Negative Self-Schema Constructing Trait Factors Underlying Susceptibility to Depression
H. Komatsu (2021)
10.1038/s41398-021-01488-3
Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data
D. Taliaz (2021)
10.12740/pp/onlinefirst/115191
Use of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of drug-resistant depression - a pilot study, presentation of five clinical cases.
A. Antosik-Wojcinska (2021)
10.1136/jnnp-2020-325308
Lesional psychiatric neurosurgery: meta-analysis of clinical outcomes using a transdiagnostic approach
Benjamin Davidson (2021)
10.3390/jpm11020155
Treatment-Resistant Depression Revisited: A Glimmer of Hope
A. Halaris (2021)
10.1186/s12991-021-00365-z
The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
Marcatili Matteo (2021)
10.1101/2021.01.21.20248810
Reduction of brooding and more general depressive symptoms after fMRI neurofeedback targeting a melancholic functional-connectivity biomarker
J. Taylor (2021)
10.1038/s41398-021-01581-7
Predictive values of tumor necrosis factor-α for depression treatment outcomes: effect modification by hazardous alcohol consumption
Wonsuk Choi (2021)
10.1016/j.brs.2021.07.018
Accelerated theta burst stimulation for the treatment of depression: A randomised controlled trial
Leo Chen (2021)
10.3389/fphar.2021.691200
Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis
Xiaoyi Hang (2021)
10.1093/neuros/nyab112
A Novel Framework for Network-Targeted Neuropsychiatric Deep Brain Stimulation
A. Allawala (2021)
10.1016/j.brs.2021.07.015
A patient-oriented analysis of pain side effect: A step to improve the patient's experience during rTMS?
Afifa Humaira (2021)
Antidepressant efficacy of oral ketamine treatment
(2021)
10.3390/jcm10174028
The Acute Effects of Aerobic Exercise on Nocturnal and Pre-Sleep Arousal in Patients with Unipolar Depression: Preplanned Secondary Analysis of a Randomized Controlled Trial
Gavin Brupbacher (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar